The antibiotic resistance crisis: Part 1: causes and threats

P and T

Volumn 40, Issue 4, 2015, Pages 277-283

  Ventola, C Lee ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTAROLINE; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; METICILLIN; PENICILLIN DERIVATIVE; TETRACYCLINE; VANCOMYCIN;

ACINETOBACTER; AGRICULTURE; ANTIBIOTIC RESISTANCE; ARTICLE; COST BENEFIT ANALYSIS; DRUG ABUSE; DRUG APPROVAL; DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE; DRUG RESISTANT TUBERCULOSIS; DRUG USE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GOVERNMENT REGULATION; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; INAPPROPRIATE PRESCRIBING; LIVESTOCK; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEISSERIA GONORRHOEAE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 84926291696     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Golkar Z, Bagazra O, Pace DG. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. J Infect Dev Ctries 2014;13;8(2):129–136.
2. Gould IM, Bal AM. New antibiotic agents in the pipeline and how they can overcome microbial resistance. Virulence 2013;4(2):185–191.
3. Wright GD. Something new: revisiting natural products in antibiotic drug discovery. Can J Microbiol 2014;60(3):147–154.
4. Sengupta S, Chattopadhyay MK, Grossart HP. The multifaceted roles of antibiotics and antibiotic resistance in nature. Front Microbiol 2013;4:47.
5. Centers for Disease Control and Prevention, Office of Infectious Disease. Antibiotic resistance threats in the United States, 2013. April 2013. Available at: http://www.cdc.gov/drugresistance/ threat-report-2013. Accessed January 28, 2015.
6. Congressional Research Service Report. Life expectancy in the United States. March 2005. Available at: http://www.cnie.org/ nle/crsreports/05mar/RL32792.pdf. Accessed January 5, 2015.
7. Spellberg B, Gilbert DN. The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett. Clin Infect Dis 2014;59 suppl 2:S71–S75.
8. Viswanathan VK. Off-label abuse of antibiotics by bacteria. Gut Microbes 2014;5(1):3–4.
9. Read AF, Woods RJ. Antibiotic resistance management. Evol Med Public Health 2014;2014(1):147.
10. The antibiotic alarm. Nature 2013;495(7440):141.
11. Lushniak BD. Antibiotic resistance: a public health crisis. Public Health Rep 2014;129(4):314–316.
12. Gross M. Antibiotics in crisis. Curr Biol 2013;23(24):R1063–R1065.
13. Piddock LJ. The crisis of no new antibiotics—what is the way forward? Lancet Infect Dis 2012;12(3):249–253.
14. Bartlett JG, Gilbert DN, Spellberg B. Seven ways to preserve the miracle of antibiotics. Clin Infect Dis 2013;56(10):1445–1450.
15. Michael CA, Dominey-Howes D, Labbate M. The antibiotic resistance crisis: causes, consequences, and management. Front Public Health 2014;2:145.
16. Rossolini GM, Arena F, Pecile P, Pollini S. Update on the antibiotic resistance crisis. Clin Opin Pharmacol 2014;18:56-60.
17. Van Boeckel TP, Gandra S, Ashok A. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 2014;14(8):742–750.
18. Luyt CE, Brechot N, Trouillet JL, Chastre J. Antibiotic stewardship in the intensive care unit. Crit Care 2014;18(5):480.
19. Gelles D. Merck in $8.4 billion deal for Cubist, big maker of antibiotics. New York Times. December 8, 2014. Available at: http://dealbook.nytimes.com/2014/12/08/merck-agrees-to-acquiredrug-maker-cubist-for-9-5-billion. Accessed January 5, 2015.
20. Itani KM, Shorr AF. FDA guidance for ABSSSI trials: implications for conducting and interpreting clinical trials. Clin Infect Dis 2014;58 suppl 1:S4–S9.x